Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.
Unit of Neurosurgery, Santa Corona Hospital, 17027 Pietra Ligure, Italy.
Int J Mol Sci. 2022 Apr 9;23(8):4166. doi: 10.3390/ijms23084166.
Despite the multidisciplinary management in the treatment of glioblastomas, the average survival of GBM patients is still 15 months. In recent years, molecular biomarkers have gained more and more importance both in the diagnosis and therapy of glial tumors. At the same time, it has become clear that non neoplastic cells, which constitute about 30% of glioma mass, dramatically influence tumor growth, spread, and recurrence. This is the main reason why, in recent years, scientific research has been focused on understanding the function and the composition of tumor microenvironment and its role in gliomagenesis and recurrence. The aim of this review is to summarize the most recent discovery about resident microglia, tumor-associated macrophages, lymphocytes, and the role of extracellular vesicles and their bijective interaction with glioma cells. Moreover, we reported the most recent updates about new therapeutic strategies targeting immune system receptors and soluble factors. Understanding how glioma cells interact with non-neoplastic cells in tumor microenvironment is an essential step to comprehend mechanisms at the base of disease progression and to find new therapeutic strategies for GBM patients. However, no significant results have yet been obtained in studies targeting single molecules/pathways; considering the complex microenvironment, it is likely that only by using multiple therapeutic agents acting on multiple molecular targets can significant results be achieved.
尽管在胶质母细胞瘤的治疗中采用了多学科管理,但 GBM 患者的平均生存时间仍为 15 个月。近年来,分子生物标志物在神经胶质瘤的诊断和治疗中越来越重要。同时,人们已经清楚地认识到,构成胶质瘤的 30%左右的非肿瘤细胞,极大地影响着肿瘤的生长、扩散和复发。这就是近年来科学研究集中于了解肿瘤微环境的功能和组成及其在胶质瘤发生和复发中的作用的主要原因。本文综述的目的是总结关于驻留小胶质细胞、肿瘤相关巨噬细胞、淋巴细胞以及细胞外囊泡及其与神经胶质瘤细胞的相互作用的最新发现。此外,我们还报道了针对免疫系统受体和可溶性因子的最新治疗策略更新。了解胶质瘤细胞如何与肿瘤微环境中的非肿瘤细胞相互作用,是理解疾病进展基础机制和为 GBM 患者寻找新治疗策略的重要步骤。然而,针对单一分子/途径的研究尚未取得显著成果;考虑到复杂的微环境,很可能只有通过使用多种针对多个分子靶点的治疗药物,才能取得显著的效果。